QRISK3

QRISK3: UK-calibrated 21-variable 10-year CVD risk calculator (NICE endorsed).

Demographics

Age (25–84 yrs)

Sex

Ethnicity

Cardiovascular

Conditions & Habits

Current Smoker

Diabetes

Family Hx of Premature CVD

Atrial Fibrillation

Rheumatoid Arthritis

CKD Stage

Deprivation (Townsend)

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Primary prevention CV risk assessment in UK and similar healthcare systems

Adults aged 25–84 years without prior CVD or diabetes

NICE (UK) guideline–endorsed tool for statin decision-making

More comprehensive than Framingham / ASCVD (21 variables)

Accounts for ethnicity, social deprivation, family history, lifestyle factors

Key Features

Includes deprivation (Townsend score) — UK-specific

Ethnicity-adjusted estimates (White, Asian, Afro-Caribbean, Chinese)

Incorporates atrial fibrillation, chronic kidney disease, systemic autoimmune disease

Medications: corticosteroids, hormone replacement therapy, antipsychotics

More granular than ASCVD; often used in UK primary care

How it Works

Key Variables (21 total)

Age, sex, ethnicity

SBP, HDL/Total cholesterol ratio

Smoking, diabetes, hypertension treatment

BMI, family history (premature CVD)

Atrial fibrillation, CKD stages 3–5

Rheumatoid arthritis, SLE, severe mental illness

Migraine, being on corticosteroids

Social deprivation (Townsend quintile)

Risk Stratification

10-Year CVD Risk (%)	Risk Category	NICE Recommendation
<10	Low	Lifestyle; reassess 5 yrs
10–20	Intermediate	Consider statin if >10% (individualise)
>20	High	Statin therapy recommended
>20 + lifestyle	Very High	Statin ± ezetimibe/PCSK9i

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

WHO NewsJul 2, 2026

WHO adds first diagnostic test for Ebola Bundibugyo virus to its Emergency Use Listing

Clinical Context

We think this has broad domain relevance to QRISK 3.

BJOGJun 25, 2026

Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

Clinical Context

We think this has broad domain relevance to QRISK 3.

QRISK3

When to Use

When to Use

Key Features

How it Works

Key Variables (21 total)

Risk Stratification

Clinical Pearls

QRISK3 vs. ASCVD/Framingham

Clinical Implementation

Next Steps

QRISK3 <10% (Low Risk)

QRISK3 10–20% (Intermediate)

QRISK3 >20% (High+)

Complementary Calculators

The Evidence

Primary Publication

Development and validation of QRISK3.

Origins & History

Development

Recent Journal Updates

QRISK3

When to Use

When to Use

Key Features

How it Works

Key Variables (21 total)

Risk Stratification

Clinical Pearls

QRISK3 vs. ASCVD/Framingham

Clinical Implementation

Next Steps

QRISK3 <10% (Low Risk)

QRISK3 10–20% (Intermediate)

QRISK3 >20% (High+)

Complementary Calculators

The Evidence

Primary Publication

Development and validation of QRISK3.

Origins & History

Development

Recent Journal Updates